3,5-二溴-2,4-二羟基苯甲醛 | 116096-91-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3,5-二溴-2,4-二羟基苯甲醛
• 英文名称: 3,5-dibromo-2,4-dihydroxybenzaldehyde
• CAS: 116096-91-4
• 化学式: C₇H₄Br₂O₃
• mdl: MFCD00504306
• 分子量: 295.915
• InChiKey: JEFPULPKKGELPK-UHFFFAOYSA-N

物化性质

• 熔点：
  204 °C
• 沸点：
  257.4±35.0 °C(Predicted)
• 密度：
  2.270±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P280,P305+P351+P338,P304+P340
• 危险性描述：
  H302
• 储存条件：
  2-8°C，惰性气体

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 3,5-Dibromo-2,4-Dihydroxybenzaldehyde
: OTV000378
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 4), H302
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R22
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
Harmful if swallowed.
Precautionary statement(s) none
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 295,92 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
3,5-Dibromo-2,4-Dihydroxybenzaldehyde
Acute Tox. 4; H302 <= 100 %
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
3,5-Dibromo-2,4-Dihydroxybenzaldehyde
Xn, R22 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
No data available
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3,5-二溴-2,4-二羟基苯甲醛 在 吡啶 、 偶氮二甲酸二异丙酯 、 硫酸 、 三苯基膦 、 copper(l) chloride 作用下， 以 四氢呋喃 、 水 、 乙二醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 35.0h， 生成 altissimacoumarin D
  参考文献：
  名称：

  Total Synthesis of Altissimacoumarin D, a Small Molecule Sirtuin1 Activator

  摘要：

  The total synthesis of the plant natural product altissimacoumarin D was achieved by the Mitsunobu alkylation of isofraxidin by geraniol. Isofraxidin was prepared from 2,4-dihydroxybenzaldehyde in five steps. The key reaction was the Knoevenagel condensation of an ortho-hydroxybenzaldehyde with Meldrum's acid under neutral conditions in water and one-pot acid catalyzed cyclization to the coumarin.

  DOI：

  10.21577/0103-5053.20180021
• 作为产物：
  描述：

  2,4-二羟基苯甲醛 在 pyridinium bromochromate 作用下， 以 溶剂黄146 为溶剂， 以95%的产率得到3,5-二溴-2,4-二羟基苯甲醛
  参考文献：
  名称：

  溴铬酸吡啶鎓：一种新型的溴化羟基芳族化合物的高效试剂

  摘要：

  溴铬酸吡啶鎓（PBC）已被用作有效和选择性的核溴化剂，用于溴化各种取代的羟基苯乙酮，醛和酚。

  DOI：

  10.1016/s0040-4039(03)01071-2

文献信息

• Two-Photon Uncaging with Fluorescence Reporting:  Evaluation of the <i>o</i>-Hydroxycinnamic Platform
  作者：Nathalie Gagey、Pierre Neveu、Chouaha Benbrahim、Bernard Goetz、Isabelle Aujard、Jean-Bernard Baudin、Ludovic Jullien

  DOI：10.1021/ja0722022

  日期：2007.8.1

  same time, uncaging releases a strongly fluorescent coproduct that can be used as a reporter for quantitative substrate delivery. The quantum yield of double bond photoisomerization leading to uncaging after one-photon absorption mostly lies in the 10% range. Taking advantage of the favorable photophysical properties of the uncaging coproduct, we use a series of techniques based on fluorescence emission

  本文评估了 o-羟基肉桂酸平台，用于设计具有单光子和双光子激发荧光报告的高效笼罩基团。通过偶联商业或现成的合成子，模型肉桂酸酯很容易一步制备。它们表现出大的单光子吸收，可以在近紫外范围内进行调整。通过 1 H NMR、UV-vis 吸收和稳态荧光发射研究单光子激发后的解笼锁。在整个研究系列中，笼底物在光解时定量释放。同时，uncaging 会释放强荧光副产物，可用作定量底物递送的报告基因。单光子吸收后导致解笼锁的双键光异构化的量子产率大多在 10% 范围内。利用解笼锁副产物有利的光物理特性，我们使用一系列基于荧光发射的技术来测量本肉桂酸酯的双光子激发的解笼锁横截面。在 750 nm 处显示 1-10 GM 范围内的值，它们与迄今为止报道的最有效的笼养组相比令人满意。值得注意的是，正如在活斑马鱼胚胎中观察到的结果所暗示的那样，双光子激发的解笼锁行为在体内得以保留。从目前收集到的数据的分析中提
• Benzaldehyde thiosemicarbazone derivatives against replicating and nonreplicating Mycobacterium tuberculosis
  作者：Galyna P. Volynets、Michail A. Tukalo、Volodymyr G. Bdzhola、Nataliia M. Derkach、Mykola I. Gumeniuk、Sergiy S. Tarnavskiy、Sergiy A. Starosyla、Sergiy M. Yarmoluk

  DOI：10.1038/s41429-019-0140-9

  日期：2019.4

  In this article, we report a series of benzaldehyde thiosemicarbazone derivatives possessing high activity toward actively replicating Mycobacterium tuberculosis strain with minimum inhibitory concentration (MIC) values in the range from 0.14 to 2.2 μM. Among them, two compounds—2-(4-phenethoxybenzylidene)hydrazine-1-carbothioamide (13) and 2-(3-isopropoxybenzylidene)hydrazine-1-carbothioamide (20)

  在本文中，我们报告了一系列苯甲醛硫代半碳酰胺衍生物，它们对主动复制的结核分枝杆菌菌株具有很高的活性，其最小抑菌浓度（MIC）值在0.14至2.2μM的范围内。其中，2-（4-苯氧基苄叉基）肼-1-甲硫酰胺（13）和2-（3-异丙氧基苄叉基）肼-1-甲硫酰胺（20）两种化合物也显示了在低氧下使用MIC对结核分枝杆菌具有超微摩尔的抗分枝杆菌活性。值分别为0.68和0.74μM。化合物13和20对5种耐异烟肼，利福平和氟喹诺酮类药物具有活性结核分枝杆菌的分离物与市售抗结核药相似。化合物13和20具有良好的ADME性质，并且对人肝细胞（HepG2）的细胞毒性较低。因此，2-（4-苯乙氧基亚苄基）肼-1-甲硫酰胺（13）和2-（3-异丙氧基亚苄基）肼-1-甲硫酰胺（20）是进一步临床前研究的有价值的候选者。
• Synthesis of new representatives of 11,12-dihydro-5<i>H</i>-5,11-epoxybenzo[7,8]oxocino[4,3-<i>b</i>]pyridines – structural analogues of <i>integrastatins A, B</i>
  作者：Ivan V. Kulakov、Alena L. Stalinskaya、Semyon Y. Chikunov、Yuri V. Gatilov

  DOI：10.1039/d0nj06117d

  日期：——

  The Claisen–Schmidt condensation reaction of 3,5-diacetyl-2,6-dimethylpyridine with salicylic aldehyde in the presence of an acid unexpectedly afforded 1-((5S,11S)-2,5-dimethyl-11,12-dihydro-5H-5,11-epoxybenzo[7,8]oxocino[4,3-b]pyridin-3-yl)ethan-1-one as the product of intramolecular cyclization instead of α,β-unsaturated ketones (mono- or bis-azachalcones). The obtained 1-((5S,11S)-2,5-dimethyl-11

  在酸存在下3,5-二乙酰基2,6-二甲基吡啶与水杨醛的Claisen-Schmidt缩合反应出乎意料地提供了1-（（5 S，11 S）-2,5-二甲基-11,12-二氢-5 H -5,11-环氧苯并[7,8]氧辛基[4,3 - b ]吡啶-3-基）乙烷-1-酮作为分子内环化的产物，而不是α，β-不饱和酮（单-或bis-azachalcones）。获得的1-（（5 S，11 S）-2,5-二甲基-11,12- dihydro-5 H -5,11-环氧苯并[7,8]氧辛基[4,3 - b ]吡啶-3- yl）than-1-one是HIV-1整合酶的天然抑制剂，即整合素A和B的紧密含氮结构类似物，含有四环环氧苯并氧杂环丁烷片段的表霉素C和表康康酮A。研究了对环化反应的底物范围和机理的见解。已显示用亚硒酸将氧辛环的亚甲基选择性氧化成羰基的可能性证明了合成的含吡啶类似物与整合他汀骨架的结构相似性。
• Hydrazide-containing CFTR inhibitor compounds and uses thereof
  申请人：Verkman Alan

  公开号：US20050239740A1

  公开（公告）日：2005-10-27

  The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more hydrazide-containing compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients and/or adjuvants. The methods of the invention comprise, in certain embodiments, administering to a patient suffering from a CFTR-mediated disease or condition, an efficacious amount of a hydrazide-containing compound. In other embodiments the invention provides methods of inhibiting CFTR that comprise contacting cells in a subject with an effective amount of a hydrazide-containing compound. In addition, the invention features a non-human animal model of CFTR-mediated disease which model is produced by administration of a hydrazide-containing compound to a non-human animal in an amount sufficient to inhibit CFTR.

  该发明提供了用于抑制囊性纤维化跨膜传导调节蛋白（CFTR）的组合物、药物制剂和方法，这些组合物、药物制剂和方法对于研究和治疗CFTR介导的疾病和病况非常有用。该发明的组合物和药物制剂可能包括一个或多个含有肼基的化合物，并且可能另外包括一个或多个药用载体、赋形剂和/或辅助剂。该发明的方法包括，在某些实施例中，向患有CFTR介导的疾病或病况的患者施用一定量的含有肼基的化合物。在其他实施例中，该发明提供了一种抑制CFTR的方法，其中包括将患者体内的细胞与一定量的含有肼基的化合物接触。此外，该发明还提供了一种CFTR介导的疾病的非人类动物模型，该模型是通过向非人类动物施用足以抑制CFTR的肼基化合物而产生的。
• Sulfur Nitrides in Organic Chemistry. 18. Preparation and Reduction of Benzo[1,2-<i>c</i>:3,4-<i>c</i>′:5,6-<i>c</i>″]tris- and Benzo[1,2-<i>c</i>:3,4-<i>c</i>′]bis[1,2,5]thiadiazole. A Convenient Route to Benzenehexamine and 1,2,3,4-Benzenetetramine
  作者：Shuntaro Mataka、Hisao Eguchi、Kazufumi Takahashi、Taizo Hatta、Masashi Tashiro

  DOI：10.1246/bcsj.62.3127

  日期：1989.10

  Benzotris- (3) and benzobis[1,2,5]thiadiazole (4) were prepared in a moderate yield, respectively, by the reaction of tetrasulfur tetranitride (5) with halocatechols (6) and -resorcinols (7). The reduction of 3 and 4 with Sn powder in a mixture of concentrated hydrochloric acid and dioxane gave benzenehexamine (1) and 1,2,3,4-benzenetetramine (2a) and its 5-methyl derivative (2b) in good yields, as

  通过四氮化四硫 (5) 与卤代儿茶酚 (6) 和间苯二酚 (7) 的反应，分别以中等产率制备苯并三- (3) 和苯并双 [1,2,5] 噻二唑 (4)。在浓盐酸和二恶烷的混合物中用锡粉还原 3 和 4 得到苯六胺 (1) 和 1,2,3,4-苯四胺 (2a) 及其 5-甲基衍生物 (2b)，收率良好，如分别是稳定的三盐酸盐 (1·3HCl) 和二盐酸盐 (2·2HCl)。